MannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico
October 12 2017 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced the
company’s support for Hurricane Maria victims in Puerto Rico with a
donation of Afrezza® (insulin human) inhalation power. The donation
will be delivered via American Family Airlift (AFA), a relief
organization established by Hector Hoyos and Dr. Cesar Sierra —two
Puerto Rican natives passionate about helping those in need.
Dedicated to gathering medical supplies and helping coordinate the
airlift of these medical supplies to Puerto Rico, the AFA has
partnered with a number of hospitals and organizations to assist
with their relief efforts.
“Puerto Rico has one of the highest percentages
of adults with diabetes in the United States,”1 said Michael
Castagna, Chief Executive Officer of MannKind Corporation. “It is
our duty to help. Hundreds of thousands of residents have been
significantly impacted by Hurricane Maria, many of them with
diabetes. With so many people unable to gain access to their
medical supplies, having access to an inhaled insulin such as
Afrezza, can provide support to adults living with diabetes in the
affected communities.”
Available by prescription only, Afrezza is a
rapid-acting inhaled insulin used to improve glycemic control in
adults with diabetes. This is the second donation, of Afrezza,
MannKind has made over the past two months to help with relief
efforts for recent hurricanes. For more information, including
important safety information, on Afrezza, visit www.afrezza.com.
“Recovering from a disaster, such as the one
left behind by Hurricane Maria, is challenging,” said Castagna. “We
hope that our support of people with diabetes will provide some
relief on their long road to recovery, and we will continue to
assess opportunities to assist people who, by circumstance, have no
access to their supplies.”
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
focuses on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) inhalation powder, the
Company's first FDA-approved product and the only inhaled
rapid-acting mealtime insulin in the United States, where it is
available by prescription from pharmacies nationwide. MannKind is
headquartered in Westlake Village, California, and has a
state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
References
- Centers for Disease Control and Prevention. National Diabetes
Statistics Report, 2017. CDC website.
https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
Accessed October 2017.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
risks and uncertainties. Words such as "believes", "anticipates",
"plans", "expects", "intend", "will", "goal", "potential" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon the
MannKind's current expectations. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, the risks
detailed in MannKind's filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2016 and subsequent periodic reports on Form
10-Q and current reports on Form 8-K. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact:Rose AlinayaSVP, Investor
Relations818-661-5000ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024